Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Tuesday. The brokerage issued a sell rating on the stock.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ:SYRS opened at $0.04 on Tuesday. The business has a 50 day simple moving average of $0.07 and a two-hundred day simple moving average of $0.54. Syros Pharmaceuticals has a 1 year low of $0.02 and a 1 year high of $6.93. The firm has a market capitalization of $1.04 million, a PE ratio of -0.01 and a beta of 1.31.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC boosted its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 298,575 shares of the company’s stock after purchasing an additional 139,400 shares during the quarter. Exome Asset Management LLC owned about 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.